Literature DB >> 28612841

IL-17-driven intestinal fibrosis is inhibited by Itch-mediated ubiquitination of HIC-5.

J Paul1, A K Singh1, M Kathania1, T L Elviche1, M Zeng1, V Basrur2, A L Theiss3, K Venuprasad1.   

Abstract

Intestinal fibrosis is a major complication in inflammatory bowel diseases, but the regulatory mechanism that inhibits fibrosis remains unclear. Here we demonstrate that Itch-/-myofibroblasts express increased amounts of profibrotic collagen type I and α-SMA in response to IL-17. Mechanistically, we demonstrate that Itch directly binds to HIC-5 and targets it for K63-linked ubiquitination to inhibit IL-17-driven intestinal fibrosis. Reconstitution of Itch-/- myofibroblasts with wild-type Itch but not the Itch-C830A mutant normalized the expression of profibrotic genes. Similarly, shRNA-mediated inhibition of HIC-5 normalized the expression of profibrotic gene expression. Thus, we have uncovered a novel mechanism by which Itch negatively regulates intestinal fibrosis.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28612841     DOI: 10.1038/mi.2017.53

Source DB:  PubMed          Journal:  Mucosal Immunol        ISSN: 1933-0219            Impact factor:   7.313


  45 in total

1.  TGF-beta1 slows the growth of pathogenic myofibroblasts through a mechanism requiring the focal adhesion protein, Hic-5.

Authors:  Ganary Dabiri; David A Tumbarello; Christopher E Turner; Livingston Van de Water
Journal:  J Invest Dermatol       Date:  2007-08-02       Impact factor: 8.551

2.  Hic-5 contributes to epithelial-mesenchymal transformation through a RhoA/ROCK-dependent pathway.

Authors:  David A Tumbarello; Christopher E Turner
Journal:  J Cell Physiol       Date:  2007-06       Impact factor: 6.384

Review 3.  The ubiquitin system.

Authors:  A Hershko; A Ciechanover
Journal:  Annu Rev Biochem       Date:  1998       Impact factor: 23.643

4.  Hic-5 is required for myofibroblast differentiation by regulating mechanically dependent MRTF-A nuclear accumulation.

Authors:  Scott D Varney; Courtney B Betts; Rui Zheng; Lei Wu; Boris Hinz; Jiliang Zhou; Livingston Van De Water
Journal:  J Cell Sci       Date:  2016-01-12       Impact factor: 5.285

Review 5.  Hydrogen peroxide-inducible clone 5 (Hic-5) as a potential therapeutic target for vascular and other disorders.

Authors:  Joo-ri Kim-Kaneyama; Xiao-Feng Lei; Shigeko Arita; Aya Miyauchi; Takuro Miyazaki; Akira Miyazaki
Journal:  J Atheroscler Thromb       Date:  2012-05-04       Impact factor: 4.928

6.  Noncanonical K27-linked polyubiquitination of TIEG1 regulates Foxp3 expression and tumor growth.

Authors:  Dong-Jun Peng; Minghui Zeng; Ryuta Muromoto; Tadashi Matsuda; Kazuya Shimoda; Malayannan Subramaniam; Thomas C Spelsberg; Wei-Zen Wei; K Venuprasad
Journal:  J Immunol       Date:  2011-04-06       Impact factor: 5.422

Review 7.  Medical therapy for Crohn's disease strictures.

Authors:  Gert Van Assche; Karel Geboes; Paul Rutgeerts
Journal:  Inflamm Bowel Dis       Date:  2004-01       Impact factor: 5.325

8.  Interactions among the transcription factors Runx1, RORgammat and Foxp3 regulate the differentiation of interleukin 17-producing T cells.

Authors:  Fuping Zhang; Guangxun Meng; Warren Strober
Journal:  Nat Immunol       Date:  2008-10-12       Impact factor: 25.606

9.  Isolation of primary myofibroblasts from mouse and human colon tissue.

Authors:  Hassan Khalil; Wenxian Nie; Robert A Edwards; James Yoo
Journal:  J Vis Exp       Date:  2013-10-12       Impact factor: 1.355

Review 10.  The unusual suspects--innate lymphoid cells as novel therapeutic targets in IBD.

Authors:  Rimma Goldberg; Natalie Prescott; Graham M Lord; Thomas T MacDonald; Nick Powell
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-05       Impact factor: 46.802

View more
  7 in total

Review 1.  Itch regulation of innate and adaptive immune responses in mice and humans.

Authors:  Natania S Field; Emily K Moser; Paula M Oliver
Journal:  J Leukoc Biol       Date:  2020-04-30       Impact factor: 4.962

Review 2.  Deubiquitylating enzymes: potential target in autoimmune diseases.

Authors:  Niraj Parihar; Lokesh Kumar Bhatt
Journal:  Inflammopharmacology       Date:  2021-11-18       Impact factor: 4.473

3.  Development of a Bioinformatics Framework for Identification and Validation of Genomic Biomarkers and Key Immunopathology Processes and Controllers in Infectious and Non-infectious Severe Inflammatory Response Syndrome.

Authors:  Dong Ling Tong; Karen E Kempsell; Tamas Szakmany; Graham Ball
Journal:  Front Immunol       Date:  2020-03-31       Impact factor: 7.561

Review 4.  Therapeutic Targeting of Intestinal Fibrosis in Crohn's Disease.

Authors:  Giovanni Santacroce; Marco Vincenzo Lenti; Antonio Di Sabatino
Journal:  Cells       Date:  2022-01-26       Impact factor: 6.600

5.  Pak2-mediated phosphorylation promotes RORγt ubiquitination and inhibits colonic inflammation.

Authors:  Mahesh Kathania; Ritesh Kumar; Elviche Taskem Lenou; Venkatesha Basrur; Arianne L Theiss; Jonathan Chernoff; K Venuprasad
Journal:  Cell Rep       Date:  2022-09-13       Impact factor: 9.995

6.  Hic-5 is required for activation of pancreatic stellate cells and development of pancreatic fibrosis in chronic pancreatitis.

Authors:  Lin Gao; Xiao-Feng Lei; Aya Miyauchi; Masahito Noguchi; Tomokatsu Omoto; Shogo Haraguchi; Takuro Miyazaki; Akira Miyazaki; Joo-Ri Kim-Kaneyama
Journal:  Sci Rep       Date:  2020-11-05       Impact factor: 4.379

Review 7.  The Role of E3 Ubiquitin Ligases and Deubiquitinases in Inflammatory Bowel Disease: Friend or Foe?

Authors:  Min Zou; Qi-Shan Zeng; Jiao Nie; Jia-Hui Yang; Zhen-Yi Luo; Hua-Tian Gan
Journal:  Front Immunol       Date:  2021-12-08       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.